HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease

ROCKVILLE, Md. and SEOUL, South Korea, May 3, 2024 /PRNewswire/ -- HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company committed

Related Keywords

United States ,China ,South Korea ,Seoul ,Soult Ukpyolsi ,Japan ,Indonesia ,American ,Sean Jeong ,Hanall Biopharma ,Hanall Biopharma Co Ltd ,Linkedin ,Draft Guidance On Dry Eye Drug Development ,Dry Eye Drug Development ,Beaver Dam Offspring Study ,Risk Factors ,Health Related Quality ,American Journal ,Central Corneal Staining Score ,Eye Dryness Score ,Visual Analogue Scale ,Inferior Corneal Staining Score ,Ocular Discomfort Score ,All Biopharma ,